Abstract:Rationale Enasidenib (EDB) is an orally active selective mutant isocitrate dehydrogenase‐2 enzyme inhibitor approved by the U.S. Food and Drug Administration to treat acute myeloid leukemia. It lacks a reported forced degradation study and a stability‐indicating assay method (SIAM). This study addresses this gap by establishing a degradation profile in accordance with the International Council for Harmonisation Q1A and Q1B (R2) guidelines and developing a validated SIAM for EDB. Methods EDB was exposed to forced degradation under various conditions (hydrolytic, photolytic, oxidative, and thermal stress). Degradation samples were analyzed using high‐performance liquid chromatography on an Agilent ZORBAX Eclipse Plus C18 column with a mobile phase consisting of 0.1% formic acid in Milli‐Q water and acetonitrile at a flow rate of 1 mL/min and detection at 270 nm. Liquid chromatography‐quadrupole time‐of‐flight‐high‐resolution mass spectrometry (LC/Q‐TOF HRMS) was used for the identification and characterization of degradation products. Nitrosamine risk assessment was conducted using a modified nitrosation assay procedure (NAP) test due to the presence of a secondary amine group in the drug, which is liable to forming nitrosamine drug substance–related impurities (NDSRI). Results The drug exhibited significant degradation under acidic, basic, photolytic, and oxidative conditions in the solution state. A total of nine degradation products (DP) were formed (DP‐I, DP‐III, and DP‐IV: acidic conditions; DP‐I and DP‐III: basic conditions; DP‐II, DP‐V, DP‐VI, and DP‐VII: oxidative stress; and DP‐VII, DP‐VIII, and DP‐IX: photolytic conditions), which were separated and identified using reversed‐phase high‐performance liquid chromatography and characterized using liquid chromatography–tandem mass spectrometry. The mechanism behind the formation of EDB degradation products has been discussed, and this study was the first to develop a degradation pathway for EDB. In addition, the possibilities of NDSRI formation for EDB were studied using a modified NAP test, which can contribute to the risk assessment of the drug. Conclusions Forced degradation studies were conducted by establishing a SIAM for EDB. All the degradation products were characterized by mass spectral data obtained using LC/Q‐TOF‐HRMS.

Characterization of disulfide bridges containing cyclic peptide Linaclotide and its degradation products by using LC-HRMS/MS

Efficacy and Safety of Linaclotide in Patients with Irritable Bowel Syndrome with Constipation: Chinese Sub-Cohort Analysis of a Phase III, Randomized, Double-Blind, Placebo-Controlled Trial.

Linaclotide in Irritable Bowel Syndrome with Constipation: A Phase 3 Randomized Trial in China and Other Regions

A comprehensive study on the identification and characterization of major degradation products of synthetic liraglutide using liquid chromatography‐high resolution mass spectrometry

Identification and characterization of two new oxidation degradation impurities in cinnarizine through LC‐HRMS/MS and 1H NMR, along with in silico toxicity predictions of its degradation products

Characterization of degradation products of silodosin under stress conditions by liquid chromatography/Fourier transform mass spectrometry

Forced degradation studies of elagolix sodium with the implementation of high resolution LC-UV-PDA-MS n (n=1,2,3...) and NMR structural elucidation

LC/QTOF/MS/MS characterization, molecular docking and in silico toxicity prediction studies on degradation products of anagliptin

Examining linaclotide for the treatment of chronic idiopathic constipation

Forced Degradation Studies of Elagolix Sodium with the Implementation of High Resolution LC-UV-PDA-MSn (N=1,2, 3…) and NMR Structural Elucidation

Isolation and characterization of novel degradation products in Fenoverine by LC-QTOF-MS/MS, LC-MS n and 2D-NMR

Identification and Structural Characterization of Degradation Products of Linagliptin by Mass Spectrometry Techniques

Investigation of an artificial solution degradant of linagliptin: An undesired linagliptin urea derivative generates in sample preparation of linagliptin tablet treated by sonication in acetonitrile containing diluent

An unexpected degradation pathway of N-hydroxy-5-methylfuran-2-sulfonamide (BMS-986231), a pH sensitive prodrug of HNO, in a prototype formulation solution

Randomized Trial of 2 Delayed-Release Formulations of Linaclotide in Patients With Irritable Bowel Syndrome With Constipation

Identification of major degradation products of Clorsulon drug substance including its degradation pathways by high resolution mass spectrometry and NMR

Efficacy and safety of linaclotide in treatment‐resistant chronic constipation: A multicenter, open‐label study

Method validation and characterization of stress degradation products of azelastine hydrochloride using LC‐UV/PDA and LC‐Q/TOF‐MS studies

Degradation kinetics and mechanism of an oxadiazole derivative, design of a stable drug product for BMS-708163, a γ-secretase inhibitor drug candidate.

LC/Q‐TOF‐MS‐based structural characterization of enasidenib degradation products and establishment of a stability‐indicating assay method: Insights into chemical stability

A critical assessment on stability behaviour of Vorinostat using LC-MS-QTOF with H/D exchange and NMR